ArticleDiscover oncology2026
Integrated single-cell and spatial mapping coupled with machine learning unveils core stemness landscapes and regulatory drivers in triple-negative breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTriple-negative breast cancer (TNBC) exhibits pronounced intratumoral heterogeneity, and cancer stem cells (CSCs) are thought to play a pivotal role in this process. However, the molecular regulatory mechanisms linking CSC-associated stemness features to tumor progression remain insufficiently elucidated.
methodsWe integrated single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and bulk transcriptomic data to identify high-stemness cell populations using the inferCNV and CytoTRACE algorithms. Stemness-related genes were evaluated for feature importance through hdWGCNA combined with machine learning approaches, and an XGBoost-based risk prediction model was constructed. Cellular differentiation trajectories were inferred using Monocle3 and scTour, while the effects of core genes on stemness pathways and malignant biological behaviors were assessed via CellChat analysis, SHAP attribution, and scTenifoldKnk-based virtual knockdown experiments.
resultsWe successfully established a predictive model comprising five core stemness-related genes (CALD1, ANP32B, FIS1, CD82, and APLP2), with the high-stemness score group exhibiting poorer prognosis and enhanced immune evasion. Trajectory analysis confirmed that the high-stemness subpopulation resided at the initiation stage of differentiation. Enrichment analyses revealed highly active Notch signaling communication, and virtual knockdown of hub genes effectively suppressed the expression of stemness markers such as NOTCH1. In addition, drug sensitivity analysis identified BI.2536 and related compounds as exhibiting higher therapeutic sensitivity in the high-risk group.
conclusionOur predictive model offers a novel perspective on the stemness landscape of TNBC. These core genes play key roles in maintaining stemness and also serve as potential molecular targets for personalized therapies aimed at TNBC stem-like cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.